Key result
ECMO linked to ~90% ICU survival in pregnant and postpartum women with COVID-19 ARDS.
Why the study?
The literature on the use of ECMO in peripartum women with COVID-19 is limited.
Does extracorporeal membrane oxygenation (ECMO) improve survival in pregnant and recently pregnant women with COVID-19 ARDS?
Case Report (n=10)
Does extracorporeal membrane oxygenation (ECMO) improve survival in pregnant and recently pregnant women with COVID-19 ARDS?
ECMO appears to be a viable and potentially life-saving option for pregnant and recently pregnant women with severe COVID-19 ARDS, with high rates of maternal and neonatal survival.
May support survival in refractory peripartum COVID-19 ARDS; hypothesis-generating and should not yet change practice.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung involvement is common. Patients with COVID-19 may progress to acute respiratory distress syndrome (ARDS) for which they may require mechanical ventilation. When conventional ventilation strategies are unable to achieve the desired oxygenation and gas exchange, extracorporeal membrane oxygenation (ECMO) might be an option in selected patients. The literature on the use of ECMO in peripartum women with COVID-19 is limited. We present a series of ten cases involving pregnant and recently pregnant women who rapidly developed ARDS after the onset of COVID-19 for which they received ECMO. Nine of the 10 patients survived intensive care unit discharge after a gradual recovery of their pulmonary function and weaning from mechanical ventilation and ECMO. In addition, 9 out of the 10 delivered neonates survived neonatal intensive care unit discharge.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a case report in COVID-19 and ARDS (n=10). Extracorporeal membrane oxygenation (ECMO) was evaluated on Survival to intensive care unit discharge. Extracorporeal membrane oxygenation (ECMO) in pregnant and recently pregnant women with COVID-19 and ARDS resulted in 90% (9 of 10) surviving intensive care unit discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: